-
摘要: 功能性胃肠病(functional gastrointestianal disorders，FGIDs)全球发病率高，患者生活质量差，诊断率低，对该类疾病发病机制认知不足，尤其对脑-肠互动及中枢作用的理解不深造成处置不到位及疗效不理想。本文从近年在FGIDs发病机制方面的研究热点和进展及临床难点出发，聚焦在更新FGIDs处置的理念，介绍评估体系，倡导心身同治。Abstract: Functional gastrointestinal disorders (FGIDs) present with high prevalence, poor life quality, and low diagnostic rates global. Insufficient knowledge of the pathogenesis of these disorders, specifically the brain-gut interaction and central role, resulting in indequdate optimal management and therapeutic efficacy. This article focuses on the latest research topics, progress in the pathogenesis, and the clinical uncertainties of FGIDs, emphasizes the advanced concept of management of FGIDs, introduces the evaluating system of FGIDs, and advocates psychophysiological therapy.
-
-
[1] Drossman DA, Hasler WL. Rome Ⅳ-Functional GI Disorders: Disorders of Gut-Brain Interaction[J]. Gastroenterology, 2016, 150(6): 1257-1261. doi: 10.1053/j.gastro.2016.03.035
[2] Aziz I, Palsson OS, Törnblom H, et al. The Prevalence and Impact of Overlapping Rome Ⅳ-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries[J]. Am J Gastroenterol, 2018, 113(1): 86-96. doi: 10.1038/ajg.2017.421
[3] Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study[J]. Gastroenterology, 2021, 160(1): 99-114.e3. doi: 10.1053/j.gastro.2020.04.014
[4] Ford AC, Marwaha A, Sood R, et al. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis[J]. Gut, 2015, 64(7): 1049-1057. doi: 10.1136/gutjnl-2014-307843
[5] Koloski NA, Jones M, Kalantar J, et al. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study[J]. Gut, 2012, 61(9): 1284-1290. doi: 10.1136/gutjnl-2011-300474
[6] Vanuytsel T, van Wanrooy S, Vanheel H, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism[J]. Gut, 2014, 63(8): 1293-1299. doi: 10.1136/gutjnl-2013-305690
[7] Lee IS, Wang H, Chae Y, et al. Functional neuroimaging studies in functional dyspepsia patients: a systematic review[J]. Neurogastroenterol Motil, 2016, 28(6): 793-805. doi: 10.1111/nmo.12793
[8] Keszthelyi D, Troost FJ, Masclee AA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 303(2): G141-154. doi: 10.1152/ajpgi.00060.2012
[9] Talley NJ. Functional dyspepsia: advances in diagnosis and therapy[J]. Gut Liver, 2017, 11(3): 349-357. doi: 10.5009/gnl16055
[10] Cirillo C, Bessissow T, Desmet AS, et al. Evidence for neuronal and structural changes in submucous Ganglia of patients with functional dyspepsia[J]. Am J Gastroenterol, 2015, 110(8): 1205-1215. doi: 10.1038/ajg.2015.158
[11] Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia[J]. Gut, 2014, 63(2): 262-271. doi: 10.1136/gutjnl-2012-303857
[12] Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia[J]. Am J Gastroenterol, 2011, 106(6): 1089-1098. doi: 10.1038/ajg.2010.512
[13] Ghoshal UC, Ghoshal U, Rahman MM, et al. Post-infection functional gastrointestinal disorders following coronavirus disease-19: a case-control study[J]. J Gastroenterol Hepatol, 2022, 37(3): 489-498. doi: 10.1111/jgh.15717
[14] Berčík P, De Giorgio R, Blennerhassett P, et al. Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection[J]. Gastroenterology, 2002, 123(4): 1205-1215. doi: 10.1053/gast.2002.36024
[15] 毋睿涵, 蓝宇, 何凤, 等. 幽门螺杆菌感染后功能性消化不良患者的胃黏膜肥大细胞变化[J]. 中华消化杂志, 2018, 38: (6)371-376.
[16] Verdu EF, Bercik P, Huang XX, et al. The role of luminal factors in the recovery of gastric function and behavioral changes after chronic Helicobacter pylori infection[J]. Am J Physiol Gastrointest Liver Physiol, 2008, 295(4): G664-G670. doi: 10.1152/ajpgi.90316.2008
[17] Zhang CL. Changes in patients'symptoms and gastric emptying after Helicobacter pylori treatment[J]. World J Gastroenterol, 2016, 22(18): 4585. doi: 10.3748/wjg.v22.i18.4585
[18] Oh JH, Kwon JG, Jung HK, et al. Clinical practice guidelines for functional dyspepsia in Korea[J]. J Neurogastroenterol Motil, 2020, 26(1): 29-50. doi: 10.5056/jnm19209
[19] Miwa H, Kusano M, Arisawa T, et al. Evidence-based clinical practice guidelines for functional dyspepsia[J]. J Gastroenterol, 2015, 50(2): 125-139. doi: 10.1007/s00535-014-1022-3
[20] Wauters L, Dickman R, Drug V, et al. United European Gastroenterology(UEG)and European Society for Neurogastroenterology and Motility(ESNM)consensus on functional dyspepsia[J]. United European Gastroenterol J, 2021, 9(3): 307-331. doi: 10.1002/ueg2.12061
[21] Ford AC, Tsipotis E, Yuan YH, et al. Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis[J]. Gut, 2022: gutjnl-gu2021-326583.
[22] Lee KJ, Tack J. Altered intestinal microbiota in irritable bowel syndrome[J]. Neurogastroenterol Motil, 2010, 22(5): 493-498. doi: 10.1111/j.1365-2982.2010.01482.x
[23] Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy[J]. Gut Liver, 2017, 11(2): 196-208. doi: 10.5009/gnl16126
[24] Costa MBG, Azeredo IL Jr, Marciano RD, et al. Evaluation of small intestine bacterial overgrowth in patients with functional dyspepsia through H2breath test[J]. Arq Gastroenterol, 2012, 49(4): 279-283. doi: 10.1590/S0004-28032012000400009
[25] Gibson GR, Hutkins R, Ellen Sanders M, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics(ISAPP)consensus statement on the definition and scope of prebiotics[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(8): 491-502. doi: 10.1038/nrgastro.2017.75
[26] Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome[J]. Gut, 2021, 70(7): 1214-1240. doi: 10.1136/gutjnl-2021-324598
[27] Fujiwara Y, Arakawa T. Overlap in patients with dyspepsia/functional dyspepsia[J]. J Neurogastroenterol Motil, 2014, 20(4): 447-457. doi: 10.5056/jnm14080
[28] 蓝宇, 方秀才主译. 功能性胃肠病多维度临床资料剖析: 中文翻译版[M]. 北京: 科学出版社, 2017: 72-104.
[29] Rej A, Shaw CC, Buckle RL, et al. The low FODMAP diet for IBS; A multicentre UK study assessing long term follow up[J]. Dig Liver Dis, 2021, 53(11): 1404-1411. doi: 10.1016/j.dld.2021.05.004
[30] Dinan TG, Stanton C, Long-Smith C, et al. Feeding melancholic microbes: MyNewGut recommendations on diet and mood[J]. Clin Nutr, 2019, 38(5): 1995-2001. doi: 10.1016/j.clnu.2018.11.010
[31] 中华医学会消化病学分会幽门螺杆菌学组. 2022中国幽门螺杆菌感染治疗指南[J]. 中华消化杂志, 2022, 42(11): 745-756. https://www.cnki.com.cn/Article/CJFDTOTAL-WIEC202203004.htm
[32] Ueda M, Iwasaki E, Suzuki H. Profile of acotiamide in the treatment of functional dyspepsia[J]. Clin Exp Gastroenterol, 2016, 9: 83-88.
[33] Potter MDE, Wood NK, Walker MM, et al. Proton pump inhibitors and suppression of duodenal eosinophilia in functional dyspepsia[J]. Gut, 2019, 68(7): 1339-1340. doi: 10.1136/gutjnl-2018-316878
[34] Ford AC, Harris LA, Lacy BE, et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2018, 48(10): 1044-1060. doi: 10.1111/apt.15001
[35] Barbara G, Cremon C, Bellini M, et al. Italian guidelines for the management of irritable bowel syndrome[J]. Dig Liver Dis, 2023, 55(2): 187-207. doi: 10.1016/j.dld.2022.11.015
-
计量
- 文章访问数: 2662
- PDF下载数: 5394
- 施引文献: 0
下载: